Metolazone 2.5mg Tablet

Metolazone 2.5mg Tablet is an oral thiazide-like diuretic containing 2.5mg of metolazone. It is used medically to promote the elimination of excess sodium and water and is associated with treatment of oedema and hypertension. Metolazone 2.5mg tablets are documented in current U.S. prescription product labelling, while UK NHS guidance identifies 2.5mg as an imported/unlicensed metolazone presentation rather than the licensed Xaqua strength.

Metolazone belongs to the diuretic class and is particularly used in specialist management of fluid retention associated with conditions such as heart failure and renal disease. Product availability, formulation and regulatory status vary by country.

Product Information

Generic Name

Metolazone

Strength

2.5mg

Dosage Form

Tablet

Route

Oral

Drug Class

Thiazide-like diuretic

Therapeutic Action

Diuretic / natriuretic / antihypertensive

Active Ingredient

Metolazone

Prescription Status

Prescription medicine; requirements vary by country

UK Licensed Reference

Xaqua is licensed at 5mg; 2.5mg presentations may be supplied as imported/unlicensed products

Metolazone 2.5mg and Oedema

Metolazone may be used to reduce excess fluid associated with conditions including heart failure and kidney disease.

Because diuretic treatment can alter fluid volume and electrolyte concentrations, treatment requires appropriate medical monitoring, particularly in patients receiving multiple diuretics or who have impaired renal function.

Metolazone 2.5mg and Hypertension

Metolazone has antihypertensive activity in addition to its diuretic effect. Current product information identifies hypertension as a therapeutic indication.

Blood pressure response and renal/electrolyte status may need to be monitored during treatment.

Metolazone 2.5mg and Kidney Disease

Metolazone is used clinically in patients with fluid retention associated with renal disease. However, reduced kidney function can also increase the complexity of fluid and electrolyte management.

The UK product information highlights the need for monitoring renal function and electrolytes and advises caution in patients with significant renal impairment.

Metolazone 2.5mg and Heart Failure

Metolazone is used in the management of oedema associated with congestive heart failure.

It may be used as part of specialist diuretic therapy, including in patients whose fluid retention is difficult to control with other diuretic treatment. Because combined diuretic treatment can substantially increase fluid and electrolyte losses, medical supervision is important.

Metolazone 2.5mg vs 5mg

Metolazone is manufactured in several strengths, including 2.5mg and 5mg.

The strength is not the only factor that determines the clinical effect of a metolazone product. Different metolazone formulations can have different bioavailability, and the UK MHRA has specifically warned about switching between Xaqua and other metolazone preparations.

For that reason, different metolazone products should not be treated as automatically interchangeable simply because they contain the same nominal milligram strength.

Metolazone 2.5mg and Xaqua 5mg

This is an important UK distinction.

Metolazone 2.5mg is the active-ingredient strength of the product described on this page.

Xaqua 5mg is a specific UK-licensed metolazone product manufactured by Renascience Pharma Ltd. Current UK NHS guidance states that Xaqua is available as 5mg tablets and that imported metolazone products have historically included 2.5mg presentations.

Therefore, an unspecified Metolazone 2.5mg Tablet should not automatically be marketed as “generic Xaqua 2.5mg”, because Xaqua is not licensed in the UK at 2.5mg.

Metolazone 2.5mg and Zaroxolyn

Zaroxolyn® is a brand associated with metolazone and has a documented 2.5mg presentation. Current U.S. prescribing information identifies Zaroxolyn as metolazone and describes 2.5mg and 5mg tablets.

However, different metolazone formulations may have different bioavailability. U.S. product labelling explicitly warns that formulations equivalent to Zaroxolyn and formulations equivalent to Mykrox should not be interchanged because they are not therapeutically equivalent at the same doses.

Monitoring During Metolazone Treatment

Because metolazone affects fluid and electrolyte balance, monitoring may include:

• Serum electrolytes
• Renal function
• Blood pressure
• Fluid status
• Clinical signs of dehydration or electrolyte disturbance

The need and frequency of monitoring depend on the patient's condition, kidney function and concurrent medicines.

Metolazone 2.5mg Availability in the UK

The UK regulatory position is important for this strength.

Current UK eMC information lists Xaqua 5mg Tablets as the licensed metolazone product, while NHS prescribing guidance states that imported metolazone presentations include 2.5mg tablets.

This means a Metolazone 2.5mg product should not automatically be described as a UK-licensed medicine. The specific manufacturer, country of origin and regulatory status should be checked before supply.

International Availability

Metolazone 2.5mg tablets are established in international prescription markets. Current U.S. product information lists Metolazone Tablets USP 2.5mg, including commercial and institutional presentations.

Other markets may use different brands and formulations, including products marketed under metolazone or brand-specific names. Regulatory approval, reimbursement, prescription requirements and product availability should be verified for each country.

How it works

Metolazone reduces the reabsorption of sodium and chloride in the renal tubules. This increases the amount of sodium and water eliminated in the urine, producing a diuretic effect.

Its thiazide-like action can remain clinically useful in patients with reduced renal function, which is one reason metolazone is used in specialist fluid-management strategies.

Metolazone is used to help manage oedema, or excess fluid accumulation, and hypertension.

Diuretic therapy can be used in fluid retention associated with cardiovascular or renal conditions. Metolazone may also be used in specialist diuretic regimens when additional fluid removal is clinically required.

U.S. prescribing information identifies metolazone for the treatment of oedema associated with congestive heart failure and renal disease and for hypertension.

The current UK Xaqua indication includes oedema associated with kidney disease, oedema associated with congestive heart failure and mild to moderate hypertension.

Metolazone 2.5mg Storage

Storage requirements depend on the specific manufacturer and product.

For example, current U.S. metolazone 2.5mg tablet labelling specifies controlled room-temperature storage and protection from light.

Always follow the storage instructions printed on the actual product packaging.

Metolazone can cause clinically significant changes in fluid balance and electrolytes.

Potential adverse effects include:

• Hypokalaemia
• Hyponatraemia
• Hypomagnesaemia
• Hypochloraemia
• Dehydration
• Hypotension
• Dizziness
• Headache
• Fatigue
• Gastrointestinal symptoms
• Muscle cramps
• Changes in renal function
• Increased uric acid or glucose levels

The UK Xaqua SmPC highlights electrolyte abnormalities, hypotension, renal effects and other adverse reactions associated with metolazone treatment.

Patients with significant kidney disease, liver disease or pre-existing electrolyte disturbances require particular clinical attention.

Metolazone 2.5mg Interactions

Metolazone can interact with medicines that affect renal function, blood pressure or electrolyte balance.

Clinically relevant interaction categories include:

• Loop diuretics, which can increase diuresis and electrolyte loss.
• NSAIDs, which can reduce diuretic effects and increase renal risk.
• Lithium, because diuretics can increase lithium exposure.
• Cardiac glycosides, particularly where hypokalaemia increases toxicity risk.
• Corticosteroids, which may increase potassium loss.
• Other antihypertensive medicines, which can increase hypotension.
• Other medicines affecting electrolyte balance or renal function.

A healthcare professional should review the complete medication list before treatment.